Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2023 | Emerging biomarkers of prognosis in MS

Burcu Zeydan, MD, Mayo Clinic, Rochester, MN, offers insights into emerging imaging biomarkers that play a pivotal role in multiple sclerosis (MS) prognostication. Notably, paramagnetic rim lesions, identified through MRI or PET, exhibit a correlation with earlier disability and a more aggressive disease course. Additionally, retinal nerve fibre layer thickness is linked to a poorer prognosis. Myelin imaging and microglia activity assessments via PET are also emerging as promising imaging tools. Serum and cerebrospinal fluid (CSF) neurofilament light chain also demonstrates promising predictive value for disability worsening, disease activity, and treatment response. However, it’s worth noting that this measure is non-specific. Lastly, artificial intelligence (AI) is emerging as a valuable tool for numerous aspects of MS research and clinical care. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.